Table 4.
Long‐term outcome post‐LVAD explant for recovery patients
| Follow‐up time (months) | 26 (0.3–73) |
| Primary outcome | |
| Ongoing after explant | 26 (92.8%) |
| HF recurrence | 3 (10.7%) |
| LVAD reimplantation | 1 (3.6%) |
| Death | 1 (3.6%) |
| BMI(kg/m2) | 27.6 [25.4–29.7] |
| Blood pressure (mmHg) | |
| Systolic | 113 (88–160) |
| Diastolic | 77 (51–98) |
| Mean arterial pressure | 90 (68–113) |
| Echocardiography data | |
| LVEF (%) | 40 (15–60) |
| LVEDD (mm) | 54 (41–74) |
| LVESD (mm) | 43 (27–63) |
| MR grade ≥3 | 2 |
| ECG | |
| Heart rate (b.p.m.) | 73 (48–105) |
| Rhythm | |
| Sinus | 21 (75%) |
| Atrial fibrillation/flutter | 3 (10.7%) |
| Other | 4 (14.3%) |
| QRS width (ms) | 98 (74–188) |
| QTc duration (ms) | 435 (374–593) |
| Blood chemistry | |
| Creatinine (μmol/L) | 97 (62–248) |
| Bilirubin (mg/dL) | 0.6 (0.3–2.8) |
| Functional status at last follow‐up | |
| NYHA Class I | 7 (25%) |
| NYHA Class II | 16 (57.2%) |
| NYHA Class III | 3 (10.7%) |
| Unknown | 2 (7.1%) |
| HF medication | |
| Beta‐blockers | 24 (85.7%) |
| ACE inhibitors | 20 (71.4%) |
| Loop diuretics | 14 (50%) |
| Inflow cannula in situ | 3 (10.7%) |
| Anticoagulation/anti‐platelet therapy | 20 (71.4%) |
| Acetylsalicylic acid | 12 (42.9%) |
| Vitamin K antagonist | 11 (39.3%) |
| Both | 4 (14.3%) |
| None | 8 (29%) |
| Number of patients with CVA | 0 (0%) |
ACE, angiotensin‐converting enzyme; BMI, body mass index; CVA, cerebrovascular accident; ECG, electrocardiogram; HF, heart failure; LVAD, left ventricular assist device; LVEDD, left ventricular end‐diastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end‐systolic diameter; MR, mitral regurgitation; NYHA, New York Heart Association.
Values are median (range), mean [standard deviation], or n (%).